Fig. 1.

Improved PFS is alloreactive NK cell dose dependent. Shown are PFS curves of one experiment where Balb/c mice were injected s.c. with 4T1 breast cancer at day 0 and either left untreated or treated with chemo-irradiation at days 8 and 9 (indicated by the symbol) followed by transfer of NK cells from various mouse strains with different numbers of alloreactive NK cells toward the Balb/c-type tumor at day 10 (indicated by the arrow, 10 mice per group; “b/d” (CB6F1) mice have half the number of alloreactive NK cells than “b” (B6) or “b/k” (B6CBAF1) mice). a The PFS of each treatment group separately and b The PFS of recipients of equal doses of alloreactive NK cells grouped together. *Statistical significant difference (p < 0.01) of the PFS of mice treated with 5 × 10⁶ b/k NK cells compared with PFS of mice without NK cell treatment as well as with the groups that received the same 2× higher number of alloreactive NK cells (i.e., 5 × 10⁶ b or b/k NK cells or 10 × 10⁶ b/k NK cells) taken together